RenovoRx(RNXT)
$1.22+0.04 (+3.39%)
RNXT
RenovoRx earnings date
$1.22
At close:+0.04 (+3.39%)
Want to see RNXT full AI Analyst Report?
RenovoRx (RNXT) Q3 2026 Earnings Report
208 Followers
RNXT Q3 2026 EPS Results
- Actual EPS
- -$0.08
- Consensus EPS
- -$0.06
- Beat/Miss
- Missed by -$0.02
- One Year Ago EPS
- -$0.08
RNXT Q3 2026 Revenue Results
- Actual Revenue
- $1.07M
- Expected Revenue
- $1.06M
- Beat/Miss
- Beat by +$2,000
- YoY Revenue Growth
- +300.75%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
RNXT Upcoming Earnings
RenovoRx's next earnings date is estimated for April 6, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
RNXT Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive, with record revenue, strong sequential and year-over-year growth, expansion in active commercial centers and the sales pipeline, completion of Phase III enrollment, new clinical evidence, broader use cases and a maintained revenue outlook. The company continues to report net losses and higher selling, general and administrative expenses, while the impact of emerging pancreatic cancer therapies remains uncertain, but these challenges were outweighed by the reported commercial and clinical progress.
Company Guidance
RenovoRx is maintaining its full year 2026 revenue guidance of $3.75 million to $4.25 million and remains confident in its ability to meet its year-end 2026 target of 36 active commercial cancer center customers; it expects initial top line data from the Phase III TIGeR-PaC trial in the second half of 2027, believes its cash position provides sufficient runway to fund operations into the second half of 2027, expects operating losses to narrow further as it advances towards its goal of sustained profitability, and continues to work towards its goal of cash flow positive operations.
- Record Quarterly RevenueThird-quarter 2026 revenue reached a record $1.07 million, exceeding the $1 million threshold for the first time. Revenue increased approximately 17% sequentially and was more than 4x higher than the $266,000 reported in the third quarter of 2025, representing nearly a 300% year-over-year increase.
- Strong Year-to-Date Revenue GrowthRevenue for the first nine months of 2026 was approximately $2.5 million, more than double RenovoRx's full-year 2025 revenue of $1.1 million.
- Expansion of Active Commercial CentersActive commercial cancer centers increased from 21 at the end of the second quarter to 26 at the end of the third quarter. Management remains confident in achieving its year-end 2026 target of 36 active commercial cancer centers.
- Growing Commercial PipelineBeyond the 26 active centers, more than 40 additional centers were in various stages of evaluation, approval or activation, representing a total commercial funnel of more than 65 centers.
- Fully Staffed and Focused Sales OrganizationRenovoRx completed the build-out of its sales organization with a Vice President of Sales and Market Development and five regional market development managers. Management stated that approximately 98% of pancreatic cancer diagnoses occur within roughly 200 cancer centers, with the top 25 centers accounting for about 40% and the top 100 centers representing more than 75% of U.S. diagnoses.
- Repeat Ordering and Physician AdoptionThe company continued to see strong repeat ordering from the majority of existing customers. Management said physician-to-physician sharing, peer-reviewed publications, medical meetings and clinician discussions are contributing to RenovoCath adoption.
- Expansion Beyond Locally Advanced Pancreatic CancerA physician at an active center used RenovoCath commercially to deliver chemotherapy to a sarcoma patient, marking the first commercial use beyond locally advanced pancreatic cancer. The company also reported continuing interest in using TAMP for sarcoma.
- First Neoadjuvant Investigator-Initiated Trial Patient TreatedThe University of Vermont treated its first patient in late October in an investigator-initiated trial evaluating TAMP before surgery for patients with planned surgical resection in the neoadjuvant setting. Management described this as the first supported IIT to begin enrolling and said it reflects physician interest in exploring TAMP earlier in the disease pathway.
- Completion of Phase III TIGeR-PaC EnrollmentRenovoRx completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer at the end of August. Initial top-line data are expected in the second half of 2027.
- Positive Pharmacokinetic and Pharmacodynamic FindingsA randomized TIGeR-PaC substudy published in the Journal of Cancer Chemotherapy and Pharmacology demonstrated significant drug uptake near the tumor site with reduced systemic drug levels, providing pharmacokinetic support for TAMP's targeted drug-delivery approach.
- 2026 Revenue Guidance MaintainedRenovoRx maintained its full-year 2026 revenue guidance of $3.75 million to $4.25 million.
- Broader Treatment Pathway Through PRISM-TAMPManagement described PRISM-TAMP as an effort to move TAMP earlier in the treatment pathway for potentially Stage 2 or Stage 2/3 borderline-resectable patients. The stated treatment sequence includes upfront systemic chemotherapy, radiation therapy and then TAMP, with a slightly truncated radiation course aimed at reaching potential surgical resection faster.
- Targeted Drug-Delivery Platform PositioningTAMP is designed to deliver chemotherapy and potentially other therapies through the arterial wall near the tumor, concentrating treatment at the target site while potentially reducing toxicity compared with systemic intravenous therapy.
- Additional Peer-Reviewed Clinical EvidenceResearchers at Hackensack Meridian Health and Jersey Shore University Medical Center published a peer-reviewed case series describing their experience using TAMP in patients with locally advanced pancreatic cancer whose tumors were not surgically removable because of significant complex blood-vessel involvement despite extensive prior therapy.
- Potential Opportunity From Emerging Pancreatic Cancer TherapiesManagement said new pancreatic cancer therapies could be complementary to RenovoCath and may create opportunities to deliver established drugs locally alongside novel therapies, as well as potentially expand the range of agents delivered through the device. The company is exploring agents including oxaliplatin for metastatic pancreatic cancer.
- Intellectual Property Portfolio ExpansionThe U.S. Patent and Trademark Office issued a notice of allowance in the third quarter for a new patent covering the RenovoCath dual-occlusion catheter system. The portfolio now includes 10 issued or allowed U.S. patents, 10 issued OUS patents, 6 pending U.S. cases, 7 pending OUS cases and 2 pending PCT applications.
- Strong Gross Profit and Underlying Gross MarginThird-quarter gross profit was $878,000 with reported gross margin of 82%. Excluding three devices converted from one Phase III trial site to a commercial customer at no gross margin under GAAP, underlying gross margin was 85%, compared with approximately 84% in the first half of the year.
- Lower Research and Development ExpensesThird-quarter research and development expenses were approximately $1.2 million, down from $1.7 million in the third quarter of 2025. The decrease reflected lower Phase III TIGeR-PaC costs following completion of patient enrollment, partially offset by continued investment in investigator-initiated trial programs.
- Improved Operating Loss and Cash PositionThird-quarter loss from operations was approximately $3.2 million, improving from $3.4 million in the prior quarter. Cash and cash equivalents increased to approximately $10.4 million at September 30, 2026, from approximately $9.5 million at June 30, 2026, supported by $3.5 million of warrant exercises. Management said the cash position provides runway into the second half of 2027.
RNXT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 06, 2027 | 2026 (Q4) | -0.06- | -0.09 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.06-0.08 | -0.08 | 0.00% (+0.00) | |
| Aug 12, 2026 | 2026 (Q2) | -0.07-0.06 | -0.08 | 25.00% (+0.02) | |
| May 14, 2026 | 2026 (Q1) | -0.08-0.09 | -0.08 | -12.50% (-0.01) | |
| Apr 01, 2026 | 2025 (Q4) | -0.08-0.08 | -0.11 | 27.27% (+0.03) | |
| Nov 13, 2025 | 2025 (Q3) | -0.08-0.08 | -0.1 | 20.00% (+0.02) | |
| Aug 14, 2025 | 2025 (Q2) | -0.09-0.08 | -0.1 | 20.00% (+0.02) | |
| May 15, 2025 | 2025 (Q1) | ―-0.08 | -0.07 | -14.29% (-0.01) | |
| Apr 01, 2025 | 2024 (Q4) | -0.08-0.08 | -0.07 | -14.29% (-0.01) | |
| Nov 14, 2024 | 2024 (Q3) | -0.12-0.10 | -0.13 | 23.08% (+0.03) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
